TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Systemic Lupus Erythematosus (SLE) confirmed by Systemic Lupus International Collaborating Clinics (SLICC) classification criteria~* Moderate to severe SLE disease activity~* Evidence for at least 1 of the following SLE markers:~  * Anti-dsDNA antibodies confirmed by central laboratory or~ * Low complement confirmed by central laboratory or~ * Antinuclear antibody (ANA) titer of \>= 1:80 in combination with at least 1 of the following: Historical positivity for anti-dsDNA or Positivity for extractable nuclear antigen (anti-ENA) confirmed by central laboratory~* The subject is receiving stable SLE standard-of-care medication~Exclusion Criteria:~* Mixed connective tissue disease, scleroderma, and/or overlap syndromes of SLE~* Subjects with severe neuropsychiatric SLE or other neurological symptoms that in the opinion of the Investigator, would prevent the subject from completing protocol required procedures and assessments.~* New or worsening Class III or IV lupus nephritis~* Chronic kidney failure stage 3b~* Evidence of human immunodeficiency virus (HIV) infection, agammaglobulinemias, T-cell deficiencies, or human T-cell lymphotropic virus-1 infection at any time prior to or during the study~* Clinically significant active or latent infection (eg. chronic viral hepatitis B or C)~* Known tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent TB (LTB) infection~* Live/live attenuated vaccines within 6 weeks prior to the first study drug infusion (Visit 2) or who plan to receive these vaccines during the study or 12 weeks after the final dose of study drug~* History of thromboembolic events within 12 months of screening~* Subject has used protocol defined prohibited medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo in a specified sequence for a total of 24 weeks
- DZP dose 1 (Type: EXPERIMENTAL): Dapirolizumab pegol (DZP) dose 1 in a specified sequence for a total of 24 weeks
- DZP dose 2 (Type: EXPERIMENTAL): Dapirolizumab pegol (DZP) dose 2 in a specified sequence for a total of 24 weeks
- DZP dose 3 (Type: EXPERIMENTAL): Dapirolizumab pegol (DZP) dose 3 in a specified sequence for a total of 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Minocycline on Delirium Incidence in Critically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical or surgical patients,~* Over 18 years,~* Expected ICU stay of at least 2 days estimated by the attending intensivist,~* Agree to participate in the study~Exclusion Criteria:~* Delirium prior to inclusion,~* Diagnosis of Parkinson's disease~* Diagnosis of dementia,~* Alcohol abuse history,~* Acute neurological condition at admission~* History of psychiatric disease~* Use of antipsychotics~* Pregnant or breastfeeding women,~* Expectation of death within 2 days~* Hospitalized for exclusive palliative care~* Known allergy to minocycline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Minocycline (Type: EXPERIMENTAL): Minocycline 100 mg BID
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules identical to experimental arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* men and non-pregnant, non-breastfeeding women~* anticipated to be severely immobilized for at least 24 hours after randomization~* hospitalized with one of the following~  * congestive heart failure~ * acute respiratory failure,~ * acute infection without septic shock,~ * acute rheumatic disorders~ * acute ischemic stroke with lower extremity hemiparesis or hemi paralysis~Exclusion Criteria:~* a condition requiring prolonged anticoagulation or anti-platelets~* active bleeding or at high risk of bleeding~* contraindication to anticoagulant therapy~* general conditions in which subjects are not suitable to participate in the study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Betrixaban (Type: EXPERIMENTAL): Daily oral (PO) betrixaban capsules for 35 to 42 days and subcutaneous (SQ) injections of enoxaparin placebo for 10 ± 4 days
- Enoxaparin (Type: ACTIVE_COMPARATOR): Daily subcutaneous (SQ) injections of enoxaparin for 10 ± 4 days and oral (PO) betrixaban placebo capsules for 35 to 42 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Healthy 2 month old infants~* Available for the duration of the study and reachable by telephone~* Able to complete two blood drawing procedures during the study~Exclusion criteria:~* Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components~* Bleeding disorder, immune deficiency or significant chronic or congenital disease~* Previous receipt of blood products or immune globulin

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 98 Days
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed metastatic and/or recurrent Squamous Cell Carcinoma of Head and Neck (SCCHN) determined to be incurable by surgery and/or radiation therapy.~* Measurable disease by CT scan~* Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1~* Age: 18 years or older~* Adequate hematologic, renal, metabolic, hepatic \& thyroid function~Exclusion Criteria:~* Prior systemic treatment for metastatic and/or recurrent SCCHN~* CNS metastases, or nasopharyngeal carcinoma~* History of interstitial lung disease~* History of another primary cancer~* Any co-morbid disease that would increase risk of toxicity~  * Active infection requiring systemic treatment~ * Prior anti-Epidermal Growth Factor receptor (anti-EGFr) antibody therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Panitumumab + Docetaxel + Cisplatin
- Arm 2 (Type: OTHER): control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has the clinical diagnosis of RA for \> 3 months based on the 1987 American College of Rheumatology (ACR) classification criteria or 2010 ACR/European League against Rheumatism (EULAR) criteria.~* Participant meets the following disease activity criteria: \>= 4 swollen joints (based on 28 joint count) and \>= 4 tender joints (based on 28 joint count) at Screening and Baseline visits and disease activity score (28 joints) (DAS28) C-reactive protein (CRP) \>= 3.2 at Screening.~* Participant has an incomplete response to methotrexate. Participants must have been on oral or parental MTX therapy \>= 3 months and on a stable prescription of 15 to 25 mg/week (or \>= 10 mg/week in participants intolerant of MTX at doses \>= 15 mg/week) for \>= 4 weeks prior to the first dose of study drug. Participant must be expected to be able to continue on stable dose of MTX for the duration of study participation.~Exclusion Criteria:~* Participants previously exposed to adalimumab or other anti-tumor necrosis factor (TNF) biologics.~* Participants previously exposed to non-anti-TNF biologics or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for RA, with exception of participants exposed for less than 3 months and terminated not due to lack of efficacy or intolerability.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ABBV-3373 Followed by Placebo (Type: EXPERIMENTAL): Participants will be administered with 100 mg ABBV-3373 by intravenous infusion and placebo to adalimumab by subcutaneous injection every other week for 12 weeks. After 12 weeks, participants will receive placebo to adalimumab every other week until Week 22.
- Adalimumab (Type: EXPERIMENTAL): Participants will be administered with placebo to ABBV-3373 by intravenous infusion and 80 mg adalimumab by subcutaneous injection every other week for 12 weeks. After 12 weeks, participants will receive 80 mg adalimumab subcutaneously every other week until Week 22.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hydroxychloroquine in Primary Progressive Multiple Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent obtained~* Men and women aged of 18 and 65 years inclusive~* Who are followed at the Calgary MS Clinic~* With Primary Progressive Multiple Sclerosis, according to current diagnostic criteria~* Screening Expanded Disability Status Scale score between 4.0 and 6.5 inclusive.~* Screening timed 25 foot walk (average of two trials) of 5.5 seconds or more.~Exclusion Criteria:~* Patients undergoing treatment with antimalarial drugs, amiodarone, dapsone or digoxin~* Patients with known retinopathy~* Patients whose screening ophthalmological exam shows retinopathy~* Patients whose screening MRI scan shows gadolinium enhancing lesions~* Patients with known renal insufficiency~* Patients with known significant hepatic impairment~* Patients with known porphyria~* Patients with known allergy or other intolerability to HCQ, or to gadolinium MRI contrast agent~* Patients currently using Fampridine or 4-aminopyridine~* Patients planning to start Fampridine or 4-aminopyridine during the study period~* Patients planning to start Baclofen or Tizanidine during the duration of the study~* Patients who increase the dose of Baclofen or Tizanidine during the study period~* Patients who receive treatment with Botulinum toxin in the leg muscles during the study period~* Patients using amiodarone, dapsone, digoxin or antimalarial drugs other than HCQ~* Patients who are unable or unwilling to undergo gadolinium enhanced MRI scans~* Pregnant or breast-feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine (Type: EXPERIMENTAL): Oral Hydroxychloroquine, 200mg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Stage 1) Healthy males and females 15 months of age with no active liver disease and a negative history of hepatitis A who have been vaccinated against Haemophilus influenzae type b (Hib), diphtheria, tetanus, and pertussis diseases~* Stage 2) Healthy males and females 12 to 17 months of age with no active liver disease and a negative history of hepatitis A~Exclusion Criteria:~* Stage 1) Males and females previously vaccinated with hepatitis A vaccine, any immune deficiency, a history of allergy to any of the vaccine components, a history of seizure disorder or a neurologic disorder that would contraindicate pertussis vaccine, or a bleeding disorder~* Stage 2) Males and females previously vaccinated with hepatitis A vaccine, any immune deficiency, a history of allergy to any of the vaccine components, or a history of bleeding disorder

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 17 Months
- Healthy Volunteers: t

Study Arms:
- VAQTA™, PedvaxHIB™ and Infanrix™/VAQTA™ (Stage 1) (Type: EXPERIMENTAL): Day 1: VAQTA™ (first dose), PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.~Week 24: The second dose of VAQTA™ was administered.
- PedvaxHIB™ and Infanrix™/VAQTA™/VAQTA™ (Stage 1) (Type: EXPERIMENTAL): Day 1: PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.~Week 4: The first dose of VAQTA™ was administered.~Week 28: The second dose of VAQTA™ was administered.
- VAQTA™, PedvaxHIB™/VAQTA™ (Stage 1) (Type: EXPERIMENTAL): Day 1: VAQTA™ (first dose) and PedvaxHIB™ were administered concomitantly at different injection sites.~Week 24: The second dose of VAQTA™ was administered.
- PedvaxHIB™/VAQTA™/VAQTA™ (Stage 1) (Type: EXPERIMENTAL): Day 1: PedvaxHIB™ was administered.~Week 4: The first dose of VAQTA™ was administered.~Week 28: The second dose of VAQTA™ was administered.
- VAQTA™/VAQTA™ (Stage 2) (Type: EXPERIMENTAL): Day 1: The first dose of VAQTA™ was administered.~Week 24: The second dose of VAQTA™ was administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Minirin Versus Oxybutynin for Nocturnal Enuresis in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \>5 years old~* Nocturnal enuresis~* Candidate for pharmacological treatment~Exclusion Criteria:~* Children who their parents did noted filled the informed consent form~* Impossibility of follow up during the study period~* History of seizure~* History of rheumatologic disorders such as sjogren's disease

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Minirin (Type: EXPERIMENTAL): 120 microgram per day for 2 months, then 60 microgram per day for 2 months, then 60 microgram every two days for two months
- Oxybutynin (Type: ACTIVE_COMPARATOR): 5 mg Oxybutynin twice a daily for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sancuso® for Gastroparesis: An Open Label Study.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 65 years of age Diagnosed gastroparesis patients with symptoms of gastroparesis for at least 3 months Symptoms of nausea and vomiting of at least moderate severity using the GCSI Prior history of delayed gastric emptying as determined by scintigraphy Gastroparesis from either diabetic or idiopathic etiologies Symptoms of nausea and vomiting that have not responded adequately to conventional antiemetic agents (Compazine®, Tigan®)~Exclusion Criteria:~* Post-surgical gastroparesis Prolonged QTc on EKG Prior intolerance to 5HT3 antagonists (ondansetron or granisetron) Known hypersensitivity to granisetron or to any of the components of the patch Current treatment with ondansetron or granisetron. Patients may stop these medications for one week to enter the study. Patients will not be allowed to take ondansetron or oral granisetron during the study.~Use of ketoconazole, a medications with known drug-drug interactions with granisetron Women known to be pregnant, as determined on enrollment by a urine pregnancy test Women of childbearing potential who do not agree to use a medically approved form of contraception Nursing mothers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo followed by Sancuso (Type: OTHER): Placebo at baseline for one week followed by Sancuso® (granisetron transdermal system) 3.1 mg/24 hours for two weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male citizens of Asian countries and Australia are encouraged to enroll in the study~* patient is in a stable, monogamous sexual relationship with the same woman for at least 6 months and plans to maintain this relationship for the duration of the study~* diagnosis of premature ejaculation (PE) according to the criteria of Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) for at least 6 months before study initiation~* history of intravaginal ejaculatory latency time (IELT) of \<2 minutes in at least 3 out of 4 events~* patient's partner must have a negative urine pregnancy test at time of screening~* Exclusion Criteria:~* Not taken dapoxetine or participated in another study investigating pharmacologic treatment of PE within the last 3 months~* no history of any medical events that are associated with the development of PE~* not taken another investigational drug within 1 month, or used an experimental medical device within 6 months of study initiation~* no positive diagnosis of depressive or anxiety disorder, manic episode, panic disorder, obsessive-compulsive disorder, posttraumatic stress disorder, alcohol abuse and dependence, schizophrenia, or other psychotic disorders~* no known allergy or hypersensitivity to selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Acceptability and Efficacy of 10 Micrograms of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women aged 45 years or older. Women will be considered postmenopausal with more than 12 months since last menstrual period~* Women who have read and signed the Informed Consent Form~* Women with an intact uterus~* One or more vaginal symptoms (dryness, soreness, irritation, dyspareunia) rated as moderate to severe. Symptoms are moderate if the patient needs a treatment and feels discomfort. Symptoms are severe if the patient needs a treatment, and feels such a degree of discomfort that this could severely impact the subject's daily activities.~* Blood estradiol concentration of 30 pg/ml or less .~Exclusion Criteria:~* Women who have not signed the Informed consent Form~* Women who had a known or suspected history of breast carcinoma~* Estrogen dependent neoplasia. Women with a known, past or suspected Estrogen-dependent malignant tumours such as endometrial or ovarian cancer~* Positive or suspicious mammogram results~* Any systemic malignant disease~* Hormone therapy treatment (sex hormones or vaginal treatments or steroids) in the last three months~* Women who had abnormal vaginal bleeding or uterine bleeding of unknown cause~* Vaginal infection requiring treatment~* Previous or current venous thromboembolism (deep venous thrombosis, pulmonary embolism) Untreated endometrial hyperplasia Known thrombophilic disorders (e.g. protein C, protein S, or antithrombin deficiency) Active or previous arterial thromboembolic disease (e.g. angina, myocardial infarction) Acute liver disease, or history of liver disease as long as liver function tests have failed to return to normal Known Hypersensitivity to the active substances or to any of the excipients Porphyria~* Any serious disease or chronic condition that could interfere with study compliance~* History of thrombolytic disorders~* Use of vaginal contraceptives (DIU, vaginal ring...)~* Participation in another clinical trial in the last three months.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Estradiol 10 micrograms vaginal tablets (Type: ACTIVE_COMPARATOR): One tablet intravaginally once daily for two weeks. Thereafter one tablet twice per week with at least a 3-days interval between treatments to maintain therapeutic response.
- Promestriene 10mg./g vaginal cream (Type: ACTIVE_COMPARATOR): One application once daily intravaginally for two weeks. Thereafter one application twice per week with at least a 3-days interval between treatments to maintain therapeutic response.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete